Background. The differences in the antihypertensive treatment with angiotensin type II receptor blockers (ARBs) may be attributed to polymorphisms in genes involving drug-targeted receptor and drug metabolism. The present study aimed to investigate whether the antihypertensive effect of the ARB drug valsartan was associated with angiotensin II type 1 receptor (AGTR1) gene polymorphism (A1166 C) and cytochrome P450 enzyme 2C9 (CYP2C9) gene polymorphism (CYP2C9∗3). Methods. 281 patients with hypertension who received valsartan monotherapy in the past month were included in this retrospective study. Polymerase chain reaction-melting curve analysis was performed to genotype the AGTR1 and CYP2C9 gene polymorphisms. Based on the systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the time of visit, the patients were divided into well-controlled group (n = 144, SBP/DBP <140/90 mmHg) and poorly controlled group (n = 137, SBP/DBP ≥140/90 mmHg). Results. Older age, decreased history of drinking, a higher proportion of mild-to-moderate hypertension, lower alanine aminotransferase levels, and higher high-density lipoprotein cholesterol levels were observed in the well-controlled group than the poorly controlled group. Higher frequencies of the C allele and AC + CC genotype of AGTR1 A1166C were detected in the well-controlled than the poorly controlled patients ( = 0.005 and  = 0.006). After adjustment for demographic and environmental factors, the CC + AC genotype of AGTR1 A1166C was markedly linked to better hypertension control with valsartan treatment compared to the AA genotype (odds ratio: 2.836, 95% confidence interval: 1.199–6.705,  = 0.018). No significant difference was observed in the allele or genotype distribution of CYP2C9∗3 polymorphism between well-controlled and poorly controlled patients. Conclusions. The current data suggested that the AGTR1 A1166 C polymorphism may be associated with the antihypertensive effect of valsartan, and carriers with AC and CC genotypes may have a better antihypertensive efficacy response to valsartan treatment.

中文翻译：

---

AGTR1 A1166C 和 CYP2C9∗3 基因多态性与缬沙坦降压作用的关联

背景。血管紧张素 II 型受体阻滞剂 (ARB) 抗高血压治疗的差异可能归因于涉及药物靶向受体和药物代谢的基因的多态性。本研究旨在探讨 ARB 药物缬沙坦的降压作用是否与血管紧张素 II 1 型受体 ( AGTR1 ) 基因多态性 (A1166 C) 和细胞色素 P450 酶 2C9 ( CYP2C9 ) 基因多态性 ( CYP2C9 *3) 相关。方法。本回顾性研究纳入了过去一个月内接受缬沙坦单药治疗的 281 名高血压患者。进行聚合酶链反应熔解曲线分析以对AGTR1和CYP2C9基因多态性。根据就诊时的收缩压（SBP）和舒张压（DBP）将患者分为控制良好组（n  =144，SBP/DBP<140/90 mmHg）和控制不佳组（n  = 137，收缩压/舒张压≥140/90 毫米汞柱）。结果。在控制良好的组中观察到年龄较大、饮酒史减少、轻度至中度高血压的比例较高、丙氨酸氨基转移酶水平较低以及高密度脂蛋白胆固醇水平高于控制不良组。在控制良好的患者中检测到的 C 等位基因和AGTR1 A1166C 的 AC + CC 基因型的频率高于控制不佳的患者（ = 0.005 和 = 0.006)。在调整人口和环境因素后，与 AA 基因型相比，AGTR1 A1166C 的 CC + AC 基因型与缬沙坦治疗更好地控制高血压显着相关（优势比：2.836，95% 置信区间：1.199-6.705， = 0.018）。CYP2C9 *3 多态性的等位基因或基因型分布在控制良好和控制不佳的患者之间未观察到显着差异。结论。目前的数据表明，AGTR1 A1166 C多态性可能与缬沙坦的降压作用有关，具有AC和CC基因型的携带者对缬沙坦治疗可能有更好的降压疗效反应。